Sharon Mates - 23 Feb 2024 Form 4 Insider Report for Intra-Cellular Therapies, Inc. (ITCI)

Role
Chairman, President & CEO, Director
Signature
/s/ Lawrence J. Hineline, Attorney-in-fact
Issuer symbol
ITCI
Transactions as of
23 Feb 2024
Net transactions value
-$1,576,464
Form type
4
Filing time
27 Feb 2024, 19:59:36 UTC
Previous filing
05 Feb 2024
Next filing
05 Mar 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ITCI Common Stock Options Exercise +22,590 +2.2% 1,072,899 23 Feb 2024 Direct F1
transaction ITCI Common Stock Sale $41,034 -600 -0.06% $68.39 1,072,299 26 Feb 2024 Direct F2, F3
transaction ITCI Common Stock Sale $661,720 -9,528 -0.89% $69.45 1,062,771 26 Feb 2024 Direct F2, F4
transaction ITCI Common Stock Sale $873,711 -12,462 -1.2% $70.11 1,050,309 26 Feb 2024 Direct F2, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ITCI Restricted Stock Units Options Exercise $0 -22,590 -100% $0.000000* 0 23 Feb 2024 Common Stock 22,590 Direct F6, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Restricted stock units convert into common stock on a one-for-one basis.
F2 This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 14, 2023 and amended on June 9, 2023. A majority of the proceeds from this sale will be used to cover the reporting person's tax liability arising from the vesting of restricted stock units.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.71 to $68.69, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.79 to $69.70, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.71 to $70.625, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.
F6 Each restricted stock unit represents a contingent right to receive one share of common stock.
F7 On February 23, 2021, the reporting person was granted 67,769 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.